Electronics

Smart mirror that identifies serious illnesses

Electronics

Mobile platform that analyzes the human body and its full body metrics in 3D

Electronics

Sound-based touch input technology for smart tables and mirrors

FUSION GENOMICS: a new era in pathogen sequencing

FUSION GENOMICS is a Vancouver-based company that is advancing molecular diagnostics by developing identification tests for pathogens using proprietary technologies in combination with Next Generation Sequencing. Its ONETest™ products, in combination with the FUSIONCloud™ data analysis platform, enable rapid identification of the genetic signatures of human pathogens and cancers accurately and economically. Furthermore, FUSION’s ONETest™ platform is currently being tested at various key opinion leaders in Canada and the European Union.

by
2024.02.29

Erythra: a simple solution to difficult problems

Erythra, a biotech company, which was founded in 2018 to make use of the dynamic antigen store idea and owns the patents for it. Using this idea an innumerable number of products can be produced. Erythra's mission is to conduct research and development based on the discovery of Erythrocytes Dynamic Antigens Store (EDAS) to manufacture highly reliable medical products for the welfare of human and animal. In the establishment phase, the team are all volunteers. The shareholders and the team are mainly believing in the values that Erythra is aiming to achieve, although the expected profits are beyond calculations.

by
2024.02.29

Everwell: a user-centric technology for healthcare programs

Everwell Health Solutions is a Bangalore-based company that innovates, designs, builds and deploys user-centric technology for healthcare programs across the world. The company spun out of Microsoft Research India in 2015 by co-founders Andrew Cross and Bill Thies. Joined by Nakull Gupta, they began building a team in 2016 to champion their flagship work in digital adherence monitoring, 99DOTS, out of research and into large scale uptake in India. The company’s Everwell Hub is a comprehensive, integrated platform for adherence and patient management. Health care staff can log into a single portal to register and follow up with patients, whose adherence reports from any of its integrated technologies appear side-by-side including 99DOTS, evriMED devices, and VOT.

by
2024.02.29
Electronics

Pioneering AI-based cancer diagnostics in pathology

Pharma

XEPTAGEN provides diagnostic solutions

Electronics

Robotic rehabilitation solutions for patients suffering from a variety of neurological diseases

X-ZELL: fighting cancer, one cell at a time

X-ZELL is a global biotechnology company aiming to fundamentally reshuffle the way of diagnosing and managing one of the most pressing health issues of the time – cancer (lat. Carcinoma). The company was founded in 2014 in Singapore. Ranked among Asia’s 20 most innovative health technology start-ups, X-ZELL has developed a new platform technology capable of detecting tumour-derived Circulating Endothelial Cells (tCEC) in a small, 10mL blood sample. Long considered ‘undetectable’ in clinical routine, these ultra-rare cells help physicians diagnose clinically significant cancer early when it can be cured – in turn avoiding more than 70% of unnecessary interventions and saving billions to health systems worldwide.

by
2024.02.29

The eNose Company provides eNose for exhaled-breath analysis

The eNose Company, which was founded in 2013, focus on disease screening using exhaled-breath analysis. For this purpose, a dedicated point-of-care electronic nose was developed (Aeonose). After finishing a number of pilot studies in oncology, infectious-, and neurological diseases, The eNose Company currently focuses on colon cancer (lat. Carcinoma), lung cancer, tuberculosis (lat. Phthisis), and fasting. It develops diagnostic tools for screening of diseases through exhaled breath in order to ease patients’ lives, provide physicians with additional diagnostic tools, and lower the burden of the healthcare community. In 2014, the Aeonose received a CE-mark, and in 2015 the company was ISO 13485 certified.

by
2024.02.29

Non-surgical chin correction

Kybella is a less invasive, non-surgical option for the treatment of submental fullness invented by Kythera Biopharmaceuticals Inc. (Canada), a biopharmaceutical company focused on discovering, developing and commercializing innovative drugs and medical devices targeting large, global market opportunities.

by
2023.05.17

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.

I AGREE

#1 GROUP PROСUREMENT ORGANISATION (GPO) 

  • Focus on Biotech Brands
  • Purchasing volume €368 mln/year
  • 75 Countries
  • 100% distribution exclusivity